This is exemplified by 18% of AML patients <60 years harboring either IDH1 or IDH2 mutations, which would qualify them for the use of a targeted inhibitor but who might be excluded from receiving this therapy given their younger age. Here, IDH1 is linked to acute myeloid leukemia.